Top

BMC Ophthalmology

Published in:

Open Access 01-12-2018 | Research article

Coverage of azithromycin mass treatment for trachoma elimination in Northwestern Ethiopia: a community based cross-sectional study

Authors: Zelalem Tilahun, Teferi Gedif Fenta

Published in: BMC Ophthalmology | Issue 1/2018

Abstract

Background

Mass drug administration with antibiotics predominantly with azithromycin is one of the four arms of the SAFE strategy. The elimination of ocular chlamydial infection is only achieved as long as the azithromycin mass treatments (AMT) are given frequently enough and at a high enough coverage. This study was conducted to assess the coverage of azithromycin mass treatment and its determinants in Awi Zone, Northwestern Ethiopia.

Methods

House to house survey using a structured questionnaire was done between July 7 to July 25, 2013. Coverage is defined as the proportion of individuals in the eligible population who actually ingested the Azithromycin during the Campaign.

Results

A total of 1267 households were enrolled in the survey in which 5826 eligible members were living in these households. Almost half (54.6%) of the community members who were eligible for all six campaigns had participated in more than three campaigns of azithromycin mass treatment. The overall average self-reported coverage of the azithromycin mass treatment (AMT) in all six campaigns was 62.8% (64% in rural vs. 61.6% urban). On average, each eligible person had taken the drug 3.77 times. The rural residents were significantly more likely to have received treatment during the last round of AMT in 2012 {AOR = 2.35; 95% CI [1.80–3.06]}. Azithromycin uptake status of female household heads was less than the corresponding male household heads {AOR = 0.41; 95% CI [0.24–0.72]}. Household heads’ awareness about trachoma (AOR = 2.55; 95% CI [1.19–5.44]) and AMT {AOR = 7.19; 95% CI [3.27–15.82]} had positive association with acceptability.

Conclusion

The overall average AMT coverage was found to be low. There was low coverage of the treatment in the urban community as compared to the rural residents. Misconceptions of household heads about trachoma and azithromycin have negatively affected the coverage. Further work on why female household heads are associated with higher risk of non-participation in AMT is warranted. Strengthening awareness creation and consideration of additional campaigns is essential.

Available only for authorised users

WHO. WHO Alliance for Global Elimination of Blinding Trachoma by 2020: Weekly epidemiological record 2014; 39(89):421–428.

Mariotti SP, Pascolini D, Rose-Nussbaumer J. Trachoma: global magnitude of a preventable cause of blindness. Br J Ophthalmol. 2009;93:563–8.CrossRefPubMed

Carter Center. Summary Proceedings: Eleventh Annual Trachoma Control Program Review; Planning for Trachoma Elimination, District by District; 2010.URL: http://www.cartercenter.org/resources/pdfs/news/health_publications/trachoma/trachreview_final_eng2010.pdf (Accessed on December 2012).

FMOH. National survey on blindness, Low Vision and Trachoma in Ethiopia; 2006. http://pbunion.org/Countriessurveyresults/Ethiopia/Ethiopian_National_Blindness_and_trachoma_survey.pdf (Accessed on 05 DeC 2012).

Darougar S, Jones BR, Viswalingam M, et al. Topical therapy of hyper endemic trachoma with rifampicin, oxytetracycline or spiramycin eye ointments. Br J Ophthalmol. 1980;64:37–42.CrossRefPubMedPubMedCentral

Dawson CR, Daghfous T, Hoshiwara I, et al. Trachoma therapy with topicaltetracycline and oral erythromycin: a comparative trial. Bull World Health Organ. 1982;60:347–55.PubMedPubMedCentral

West SK, Solomon AW. Azithromycin for control of trachoma. Community Eye Health. 1999;12:55–6.PubMedPubMedCentral

Bailey RL, Arullendran P, Whittle HC, Mabey DC. Randomized controlled trial of single-dose azithromycin in treatment of trachoma. Lancet. 1993;342:453–6.CrossRefPubMed

Solomon AW, Holland MJ, Alexander NDE, Massae PA, Aguirre A, Natividad-Sancho A, Molina S, Safari S, Shao JF, Courtright P, Peeling RW, West SK, Bailey RL, Foster A, Mabey DC. Mass treatment with single dose azithromycin for trachoma. N Engl J Med. 2004;351:1962–71.CrossRefPubMed

10.

Solomon AW, Harding-Esch E, Alexander ND, Aguirre A, Holland MJ, Bailey RL, Foster A, Mabey DC, Massae PA, Courtright P, Shao JF. Two doses of azithromycin to eliminate trachoma in a Tanzanian community. New Engl J Med. 2008;358:1870–1.CrossRefPubMed

11.

Coles CL, Seidman JC, Levens J, Mkocha H, Munoz B, West S. Association of Mass Treatment with azithromycin in trachoma-endemic communities with short-term reduced risk of diarrhea in young children. Am J Trop Med Hyg. 2011; https://doi.org/10.4269/ajtmh.2011.11-0046.

12.

Keenan JD, Ayele B, Gebre T, Zerihun M, Zhou Z, House JI, Gaynor BD, Porco TC, Emerson PM, Lietman TM. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clin Infect Dis. 2011;52:883–8.CrossRefPubMedPubMedCentral

13.

Fraser-Hurt N, Bailey RL, Cousens S, Mabey D, Faal H, Mabey DCW. Efficacy of oral azithromycin versus topical tetracycline in mass treatment of endemic trachoma. Bull World Health Organ. 2001;79:632–40.PubMedPubMedCentral

14.

WHO. World Health Assembly Resolution 51.11 Global Elimination of blinding trachoma; 1998. http://www.who.int/neglected_diseases/mediacentre/WHA_51.11_Eng.pdf. Accessed 30 Nov 2012.

15.

WHO-ITI. Joint Research Agenda Meeting for the Elimination of Blinding Trachoma. Geneva: World Health. Organization; 2004.

16.

Ssemanda EN, Levens J, Mkocha H, Munoz B, West SK. Azithromycin Mass Treatment for Trachoma Control: Risk Factors for Non-Participation of Children in Two Treatment Rounds. PLoS Negl Trop Dis. 2012; https://doi.org/10.1371/journal.pntd.0001576.

17.

Melese M, Chidambaram JD, Alemayehu W, Lee DC, Yi EH, Cevallos V, Zhou Z, Donnellan C, Saidel M, Whitcher JP, Gaynor BD, Lietman TM. Feasibility of eliminating ocular chlamydia trachomatis with repeat mass antibiotic treatments. Jama. 2004;292:721–5.CrossRefPubMed

18.

University of Twente. Health Belief Model; 2013. https://www.utwente.nl/en/bms/communication-theories/sorted-bycluster/Health%20Communication/Health_Belief_Model/. Accessed 28 June 2013.

19.

Desmond N, Solomon AW, Massae PA, Lema N, Anemona A, Foster A, Mabey DW. Acceptability of azithromycin for the control of trachoma in northern Tanzania. Trans R Soc Trop Med Hyg. 2005;99:656–63.CrossRefPubMed

20.

Lwanga SK, Lemeshow S. Sample size determination for health studies: a practical manual. Geneva: World Health Organization; 1991. p. 1–5.

21.

Harding-Esch EM, Sillah A, Edwards T, Burr SE, Hart JD, Joof H, Laye M, Makalo P, Ahmed M, Molina S, Sarr-Sissoho I, Quinn TC, Lietman T, Holland MJ, Mabey D, West SK, Robin B. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Negl Trop Dis. 2013;7:e2115. https://doi.org/10.1371/journal.pntd.0002115.CrossRefPubMedPubMedCentral

22.

Central Statistics Authority. Summary and Statistical Report of the 2007 Population and Housing Census. 2008, Addis Ababa. https://searchworks.stanford.edu/view/8650186. Accessed 12 Dec 2012.

23.

Cromwell EA, King JD, McPherson S, Jip FN, Patterson AE, Mosher AW, Evans DS, Emerson PM. Monitoring of mass distribution interventions for trachoma in plateau state, Nigeria. PLoS Negl Trop Dis. 2013;7:e1995. https://doi.org/10.1371/journal.pntd.0001995.CrossRefPubMedPubMedCentral

24.

Malaty RR, Zaki SS, Said ME, Vastine DW, Dawson DW, Schachter J. Extra ocular infections in children in areas with endemic trachoma. J Infect Dis. 1981;143:853.CrossRefPubMed

25.

Blake IM, Burton MJ, Bailey RL, Solomon AW, West S, Munoz B, Holland MJ, Mabey DCW, Gambhir M, Basanez MG, Grassly NC. Estimating household and community transmission of ocular chlamydia trachomatis. PLoS Negl Trop Dis. 2009;3:e401. https://doi.org/10.1371/journal.pntd.0000401.CrossRefPubMedPubMedCentral

26.

Lakew T, House J, Hong KC, Yi E, Alemayehu W, Melese M, Zhou Z, Ray K, Chin S, Romero E, Keenan J, Whitcher JP, Gaynor BD, Lietman TM. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Negl Trop Dis. 2009;3:e376. https://doi.org/10.1371/journal.pntd.0000376.CrossRefPubMedPubMedCentral

27.

Grassly NC, Ward ME, Ferris S, Mabey DC, Bailey RL. The natural history of trachoma infection and disease in a Gambian cohort with frequent follow-up. PLoS Negl Trop Dis. 2008;2:e341. https://doi.org/10.1371/journal.pntd.0000341.CrossRefPubMedPubMedCentral

28.

Taylor KI, Taylor HR. Distribution of azithromycin for the treatment of trachoma. Br J Ophthalmol. 1999;83:134–5.CrossRefPubMedPubMedCentral

29.

Ayele B, Gebre T, House JI, Zhou Z, McCulloch CE, Porco TC, Gaynor BD, Emerson PM, Lietman TM, Keenan JD. Short report: adverse events after mass azithromycin treatments for trachoma in Ethiopia. Am J Trop Med Hyg. 2011;85:291–4.CrossRefPubMedPubMedCentral

30.

FDA. United states Food and Drug Administration safety announcement; 2013. https://www.fda.gov/downloads/Drugs/DrugSafety/UCM343347.pdf. Accessed Dec 2013.

31.

Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the Risk of Cardiovascular Death. N Engl J Med. 2012; https://doi.org/10.1056/NEJMoa1003833.

32.

Bin Abdulhak AA, Khan AR, Garbati MA, Qazi AH, Erwin P, Kisra S, Aly A, Farid T, ElChamiM WAP. Azithromycin and risk of cardiovascular death: a Meta analytic review of observational studies. Am J Ther. 2015; https://doi.org/10.1097/MJT.0000000000000138.

33.

Alemayehu D, Andrews EN, Glue P, Knirsch CA. Considerations for the design and conduct of a pharmacovigilance study involving mass drug Administration in a Resource-Constrained Setting. PLoS Negl Trop Dis. 2010; https://doi.org/10.1371/journal.pntd.0000564.

34.

Amarillo MLE, Belizario VY, Sadiang-abay JT, Sison SAM, Dayag AMS. Factors associated with the acceptance of mass drug administration for the elimination of lymphatic filariasis in Agusan del Sur, Philippines. Parasit Vectors. 2008;1:14. https://doi.org/10.1186/1756-3305-1-14.

Title: Coverage of azithromycin mass treatment for trachoma elimination in Northwestern Ethiopia: a community based cross-sectional study
Authors: Zelalem Tilahun
Teferi Gedif Fenta
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: BMC Ophthalmology / Issue 1/2018
Electronic ISSN: 1471-2415
DOI: https://doi.org/10.1186/s12886-018-0868-1

At a glance: The STEP trials

Springer Medicine

Coverage of azithromycin mass treatment for trachoma elimination in Northwestern Ethiopia: a community based cross-sectional study

Abstract

Background

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2018

Safety and satisfaction of myopic small-incision lenticule extraction combined with monovision

Evaluation of peripapillary choroidal distribution in children by enhanced depth imaging optical coherence tomography

Ocular surface health in Shanghai University students: a cross-sectional study

Association of Genes implicated in primary angle-closure Glaucoma and the ocular biometric parameters of anterior chamber depth and axial length in a northern Chinese population

Short-term changes of choroidal vascular structures after phacoemulsification surgery

IgG4-related ophthalmic disease involving extraocular muscles: case series